Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Lake Bioscience CoSHSE:600866 -0.60%70 Piotroski F-Score is 2 as of Jul. 17, 2026, which is 67% below its 10-year median of 6.00. GuruFocus rates SHSE:600866 with a GF Score™ of 70/100 and a GF Value™ of ¥5.86 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,333 Biotechnology companies, Star Lake Bioscience Co ranks worse than 72.92% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Star Lake Bioscience Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Star Lake Bioscience Co's Piotroski F-Score or its related term are showing as below:
SHSE:600866'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 6 Max: 9
Current: 2
During the past 13 years, the highest Piotroski F-Score of Star Lake Bioscience Co was 9. The lowest was 2. And the median was 6.
Star Lake Bioscience Co (SHSE:600866) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Star Lake Bioscience Co Piotroski F-Score Related Terms
Star Lake Bioscience Co Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Star Lake Bioscience Co's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600866 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Star Lake Bioscience Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Lake Bioscience Co Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Star Lake Bioscience Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Star Lake Bioscience Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was 362.108 + 178.844 + -36.236 + -46.89 = ¥458 Mil. Cash Flow from Operations was 248.937 + 1232.705 + -555.065 + -774.615 = ¥152 Mil. Revenue was 4120.288 + 3917.76 + 3822.772 + 3740.075 = ¥15,601 Mil. Gross Profit was 787.155 + 597.971 + 334.985 + 286.202 = ¥2,006 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(16397.995 + 17109.629 + 17268.052 + 17240.578 + 17390.278) / 5 = ¥17081.3064 Mil. Total Assets at the begining of this year (Mar25) was ¥16,398 Mil. Long-Term Debt & Capital Lease Obligation was ¥2,651 Mil. Total Current Assets was ¥5,927 Mil. Total Current Liabilities was ¥6,103 Mil.
Net Income was 254.685 + 171.051 + 265.932 + 474.173 = ¥1,166 Mil.
Revenue was 4286.838 + 4303.243 + 4544.828 + 4039.272 = ¥17,174 Mil. Gross Profit was 703.623 + 666.051 + 968.849 + 907.3 = ¥3,246 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(14687.215 + 14905.316 + 14307.226 + 14549.681 + 16397.995) / 5 = ¥14969.4866 Mil. Total Assets at the begining of last year (Mar24) was ¥14,687 Mil. Long-Term Debt & Capital Lease Obligation was ¥1,436 Mil. Total Current Assets was ¥7,015 Mil. Total Current Liabilities was ¥6,180 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Star Lake Bioscience Co's current Net Income (TTM) was 458.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Star Lake Bioscience Co's current Cash Flow from Operations (TTM) was 152.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Star Lake Bioscience Co's return on assets of this year was 0.02791963. Star Lake Bioscience Co's return on assets of last year was 0.07937795.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Star Lake Bioscience Co's gearing of this year was 0.15517273. Star Lake Bioscience Co's gearing of last year was 0.09594684.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Star Lake Bioscience Co's current ratio of this year was 0.97121231. Star Lake Bioscience Co's current ratio of last year was 1.13511019.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Star Lake Bioscience Co's number of shares in issue this year was 1662.753. Star Lake Bioscience Co's number of shares in issue last year was 1661.434.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Star Lake Bioscience Co's gross margin of this year was 0.12860243. Star Lake Bioscience Co's gross margin of last year was 0.18899434.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Star Lake Bioscience Co's asset turnover of this year was 0.9513904. Star Lake Bioscience Co's asset turnover of last year was 1.16932863.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
0
+
0
+
0
+
0
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Star Lake Bioscience Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Star Lake Bioscience Co (SHSE:600866) has a Piotroski F-Score of 2 as of Jul. 17, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Star Lake Bioscience Co and its competitors. This is 67% below median its historical median of 6.00. Over the past decade, Star Lake Bioscience Co's Piotroski F-Score has ranged from 2.00 to 9.00. According to the industry distribution chart, Star Lake Bioscience Co ranks #972 out of 1333 companies in the Biotechnology industry, placing it in the top 72.9%.
Is Star Lake Bioscience Co's Piotroski F-Score too high?
Star Lake Bioscience Co's current Piotroski F-Score of 2 is 67% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. The Biotechnology industry median Piotroski F-Score is 3.00. Star Lake Bioscience Co's value of 2 is 33.3% below this industry median. Based on the distribution chart, Star Lake Bioscience Co ranks #972 out of 1333 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Star Lake Bioscience Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Star Lake Bioscience Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Star Lake Bioscience Co ranks #972 out of 1333 companies for Piotroski F-Score. This places Star Lake Bioscience Co in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Star Lake Bioscience Co's value of 2 is 33.3% below this benchmark. Historically, Star Lake Bioscience Co's own Piotroski F-Score has ranged from 2.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 3.00, Star Lake Bioscience Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Lake Bioscience Co's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Star Lake Bioscience Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Lake Bioscience Co's current Piotroski F-Score is 2, which is 67% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Lake Bioscience Co stock overvalued right now?
Based on GuruFocus' analysis, Star Lake Bioscience Co (SHSE:600866) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.86, compared to a current price of ¥5.01 — trading 14.5% below its estimated fair value. The current Piotroski F-Score is 2, which is 67% below median its 10-year median of 6.00 and 33.3% below the Biotechnology industry median of 3.00. Star Lake Bioscience Co's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Star Lake Bioscience Co (SHSE:600866), the current Piotroski F-Score is 2 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Lake Bioscience Co (SHSE:600866) Overvalued in 2026?
Based on GuruFocus' analysis, Star Lake Bioscience Co stock appears to be undervalued.
The current stock price of ¥5.01 is trading 14.5% below its estimated GF Value™ of ¥5.86.
GuruFocus considers Star Lake Bioscience Co to be Modestly Undervalued.
Key valuation signals for SHSE:600866:
Piotroski F-Score: 2 (67% below median its 10-year median of 6.00)
GF Value™: ¥5.86 vs. price of ¥5.01 (14.5% below fair value)
Industry Position: 33.3% below the Biotechnology median (#972 of 1333)
No single metric tells the full story. See the SHSE:600866 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.
70GF Score
Get the complete analysis for SHSE:600866
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600866 has been successfully added to your 
